Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates

Jennifer I Smart, Gordon Ralph Corey, Martin E Stryjewski, Whedy Wang, Steven L Barriere, Jennifer I Smart, Gordon Ralph Corey, Martin E Stryjewski, Whedy Wang, Steven L Barriere

Abstract

Introduction: The broth microdilution method (BMD) for testing telavancin minimum inhibitory concentrations (MICs) was revised (rBMD) in 2014 to improve the accuracy, precision, and reproducibility of the testing method. The aim of this study was to determine the effect of the revised method on telavancin MIC values for Staphylococcus aureus (S. aureus) clinical isolates obtained from hospital-acquired pneumonia (HAP) patients.

Methods: Isolates from patients who participated in the phase 3 Assessment of Telavancin for Treatment of HAP Studies were retested using the rBMD method.

Results: Retesting of 647 isolates produced a range of telavancin MIC values from 0.015 µg/mL to 0.12 µg/mL with MIC50/90 values of 0.06/0.06 µg/mL for the total pool of samples. For methicillin-resistant S. aureus (MRSA), MIC50/90 values were 0.06/0.12 µg/mL. These values are up to 4-fold lower than MIC50/90 values obtained using the original method. These results were used in part to justify lowering the telavancin breakpoints. All tested isolates remained susceptible to telavancin at the revised susceptibility breakpoint of ≤0.12 µg/mL. Overall, the clinical cure rate for microbiologically evaluable telavancin-treated patients was 78% for S. aureus, 76% for patients with MRSA, and 79% for patients with isolates with reduced susceptibility to vancomycin (MIC ≥1 µg/mL).

Conclusion: Results from the rBMD method support the in vitro potency of telavancin against S. aureus.

Trial registration: ATTAIN (NCT00107952 and NCT00124020).

Funding: Theravance Biopharma Antibiotics, Inc.

Keywords: Hospital-acquired pneumonia; Lipoglycopeptide; Staphylococcus aureus; Telavancin; Ventilator-associated pneumonia.

Figures

Fig. 1
Fig. 1
Distribution of telavancin MICs obtained using the rBMD or original BMD method in a all S. aureus isolates, b MSSA isolates, c MRSA isolates, and dS. aureus isolates with vancomycin MICs ≥1 µg/mL. MIC minimum inhibitory concentration; MRSA methicillin-resistant S. aureus; MSSA methicillin-susceptible S. aureus; rBMD revised broth microdilution; S. aureus Staphylococcus aureus; VAN vancomycin

References

    1. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG., Jr Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–661. doi: 10.1128/CMR.00134-14.
    1. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. doi: 10.1093/cid/ciw353.
    1. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315–3320. doi: 10.1128/AAC.00113-08.
    1. Wang JL, Lai CH, Lin HH, Chen WF, Shih YC, Hung CH. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in methicillin-resistant S. aureus bacteraemia patients. Int J Antimicrob Agents. 2013;42(5):390–394. doi: 10.1016/j.ijantimicag.2013.07.010.
    1. Jacob JT, DiazGranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis. 2013;17(2):e93–e100. doi: 10.1016/j.ijid.2012.08.005.
    1. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193–200. doi: 10.1086/524667.
    1. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49(3):1127–1134. doi: 10.1128/AAC.49.3.1127-1134.2005.
    1. VIBATIV® (telavancin), USP [package insert]. South San Francisco: Theravance Biopharma US, Inc; 2016.
    1. Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009;53(8):3375–3383. doi: 10.1128/AAC.01710-08.
    1. Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis. 2015;61(Suppl 2):S58–S68. doi: 10.1093/cid/civ534.
    1. Summary of Product Characteristics (VIBATIV 250 mg powder for concentrate for solution for infusion) Bridgend, United Kingdom: Biotec Services International Limited; 2011. . Accessed Jan 4, 2016.
    1. Theravance Biopharma Announces Marketing Authorization for VIBATIV(R) (Telavancin) in Russia for Treatment of Multiple Infections Caused by Gram-Positive Bacteria, Including MRSA Dublin, Ireland: Theravance Biopharma; 2015. . Accessed Jan 4, 2016.
    1. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52(1):31–40. doi: 10.1093/cid/ciq031.
    1. Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008;52(5):1597–1603. doi: 10.1128/AAC.01513-07.
    1. Fritsche TR, Rennie RP, Goldstein BP, Jones RN. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms. J Clin Microbiol. 2006;44(8):2988–2990. doi: 10.1128/JCM.00640-06.
    1. CLSI . Performance standards for antimicrobial susceptibility testing; twenty-fourth international supplement. Wayne, PA: Clinical Laboratory and Standards Institute; 2014.
    1. Farrell DJ, Mendes RE, Rhomberg PR, Jones RN. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother. 2014;58(9):5547–5551. doi: 10.1128/AAC.03172-14.
    1. Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis. 2015;81(4):275–279. doi: 10.1016/j.diagmicrobio.2014.12.011.
    1. Mendes RE, Flamm RK, Farrell DJ, Sader HS, Jones RN. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. J Chemother; 2015:1973947815Y0000000050.
    1. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S. Clinical and Laboratory Standards Institute; 2016.
    1. Mendes RE, Sader HS, Farrell DJ, Jones RN. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother. 2012;56(7):3999–4004. doi: 10.1128/AAC.00011-12.
    1. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–872. doi: 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>;2-E.
    1. Pfaller MA, Mendes RE, Sader HS, Jones RN. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother. 2010;65(11):2396–2404. doi: 10.1093/jac/dkq335.
    1. Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2007;60(2):406–409. doi: 10.1093/jac/dkm211.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever